Kindred Biosciences (KIN) Stock Price, News & Analysis

Company Overview

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Key Stats

• Today's Range: $9.24 to $9.26
• 50-Day Range: $9.08 to $9.25
• 52-Week Range: $3.46 to $9.28
• Volume: 178,496 shs
• Average Volume: 840,890 shs
• Market Capitalization: $420.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KIN Stock Analysis - Frequently Asked Questions

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.04. The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 54.19% and a negative net margin of 529.26%.

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol-Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/05/2021
• Today: 4/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KIN
• CIK: 1561743
• Web: kindredbio.com
• Phone: (650) 701-7901
• Fax: N/A
• Employees: 63
• Year Founded: 2013

Profitability

• EPS (Most Recent Fiscal Year): ($0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,800,000.00
• Net Margins: -529.26%
• Pretax Margin: N/A
• Return on Equity: -54.19%
• Return on Assets: -39.76%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 7.02
• Quick Ratio: 7.02

Sales & Book Value

• Annual Sales: $42.16 million
• Price / Sales: 9.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.75 per share
• Price / Book: 5.29

Miscellaneous

• Outstanding Shares: 45,462,000
• Free Float: N/A
• Market Cap: $420.52 million
• Optionable: Optionable
• Beta: 1.30